Sandbox john2: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:
The [[myocardial infarction]], more than an isolated event, is a process that develops over several hours. Initially there is a central area of [[infarction]] surrounded by a border of [[ischemic]] [[myocardium]]. As time goes by, and in the absence of [[reperfusion]] measures, this area of [[ischemia]] will enlarge outwards from the central area.<ref name="pmid912839">{{cite journal| author=Reimer KA, Lowe JE, Rasmussen MM, Jennings RB| title=The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. | journal=Circulation | year= 1977 | volume= 56 | issue= 5 | pages= 786-94 | pmid=912839 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=912839  }} </ref> As this area of [[MI|infarcted myocardium]] grows, so does the chances of developing cardiogenic shock, leading to the conclusion that [[pump failure]] follows severe loss of [[myocardial]] mass. This loss usually develops over several hours, to days.<ref name="pmid4726242">{{cite journal| author=Alonso DR, Scheidt S, Post M, Killip T| title=Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. | journal=Circulation | year= 1973 | volume= 48 | issue= 3 | pages= 588-96 | pmid=4726242 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4726242  }} </ref> This conclusion is supported by the fact that most patients develop cardiogenic shock in hospital, several hours after being admitted for acute [[MI]].<ref name="pmid10985706">{{cite journal| author=Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA et al.| title=Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 3 Suppl A | pages= 1063-70 | pmid=10985706 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10985706  }} </ref><ref name="pmid7642857">{{cite journal| author=Holmes DR, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC et al.| title=Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. | journal=J Am Coll Cardiol | year= 1995 | volume= 26 | issue= 3 | pages= 668-74 | pmid=7642857 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7642857  }} </ref>
The [[myocardial infarction]], more than an isolated event, is a process that develops over several hours. Initially there is a central area of [[infarction]] surrounded by a border of [[ischemic]] [[myocardium]]. As time goes by, and in the absence of [[reperfusion]] measures, this area of [[ischemia]] will enlarge outwards from the central area.<ref name="pmid912839">{{cite journal| author=Reimer KA, Lowe JE, Rasmussen MM, Jennings RB| title=The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. | journal=Circulation | year= 1977 | volume= 56 | issue= 5 | pages= 786-94 | pmid=912839 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=912839  }} </ref> As this area of [[MI|infarcted myocardium]] grows, so does the chances of developing cardiogenic shock, leading to the conclusion that [[pump failure]] follows severe loss of [[myocardial]] mass. This loss usually develops over several hours, to days.<ref name="pmid4726242">{{cite journal| author=Alonso DR, Scheidt S, Post M, Killip T| title=Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. | journal=Circulation | year= 1973 | volume= 48 | issue= 3 | pages= 588-96 | pmid=4726242 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=4726242  }} </ref> This conclusion is supported by the fact that most patients develop cardiogenic shock in hospital, several hours after being admitted for acute [[MI]].<ref name="pmid10985706">{{cite journal| author=Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA et al.| title=Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 3 Suppl A | pages= 1063-70 | pmid=10985706 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10985706  }} </ref><ref name="pmid7642857">{{cite journal| author=Holmes DR, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC et al.| title=Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. | journal=J Am Coll Cardiol | year= 1995 | volume= 26 | issue= 3 | pages= 668-74 | pmid=7642857 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7642857  }} </ref>


These patients who develop [[shock]] after admission usually suffer of what is known as ''infarct extension'', which may result from:<ref name="pmid8452150">{{cite journal| author=Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S| title=Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. | journal=Am J Med | year= 1993 | volume= 94 | issue= 3 | pages= 265-73 | pmid=8452150 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8452150  }} </ref><ref name="pmid2738272">{{cite journal| author=Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C et al.| title=The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. | journal=J Am Coll Cardiol | year= 1989 | volume= 14 | issue= 1 | pages= 40-6; discussion 47-8 | pmid=2738272 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2738272  }} </ref>
These patients who develop [[shock]] after admission usually suffer of what is known as '''''infarct extension''''', which may result from:<ref name="pmid8452150">{{cite journal| author=Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S| title=Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. | journal=Am J Med | year= 1993 | volume= 94 | issue= 3 | pages= 265-73 | pmid=8452150 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8452150  }} </ref><ref name="pmid2738272">{{cite journal| author=Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C et al.| title=The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. | journal=J Am Coll Cardiol | year= 1989 | volume= 14 | issue= 1 | pages= 40-6; discussion 47-8 | pmid=2738272 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2738272  }} </ref>
*propagation of an [[coronary|intracoronary]] [[thrombus]];
*propagation of an [[coronary|intracoronary]] [[thrombus]];
*[[reocclusion]] of a transiently patent [[infarct]] [[artery]];
*[[reocclusion]] of a transiently patent [[infarct]] [[artery]];

Revision as of 01:33, 15 May 2014

Pathophysiology

Pathology

Myocardium

The myocardial infarction, more than an isolated event, is a process that develops over several hours. Initially there is a central area of infarction surrounded by a border of ischemic myocardium. As time goes by, and in the absence of reperfusion measures, this area of ischemia will enlarge outwards from the central area.[1] As this area of infarcted myocardium grows, so does the chances of developing cardiogenic shock, leading to the conclusion that pump failure follows severe loss of myocardial mass. This loss usually develops over several hours, to days.[2] This conclusion is supported by the fact that most patients develop cardiogenic shock in hospital, several hours after being admitted for acute MI.[3][4]

These patients who develop shock after admission usually suffer of what is known as infarct extension, which may result from:[5][6]


  • INFARCT EXTENSION AND EXPANSION
  • REMOTE ISCHEMIA
  • DIASTOLIC DYSFUNCTION
  • VALVULAR ABNORMALITIES - (page 155 article #2)

Cellular

  • ENERGY METABOLISM
  • ION PUMPS
  • NECROSIS
  • APOPTOSIS

Myocardial dysfunction

  • STUNNING
  • HIBERNATING

Reperfusion Injury

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Cardiogenic shock and Inflammatory Mediators

The Pathophysiologic "Spiral" of Cardiogenic shock

Among patients with acute MI, there is often a downward spiral of hypoperfusion leading to further ischemia which leads to a further reduction in cardiac output and further hypoperfusion. The lactic acidosis that develops as a result of poor systemic perfusion can further reduce cardiac contractility. Reduced cardiac output leads to activation of the sympathetic nervous system, and the ensuing tachycardia that develops further exacerbates the myocardial ischemia. The increased left ventricular end diastolic pressures is associated with a rise in wall stress which results in further myocardial ischemia. Hypotension reduces epicardial perfusion pressure which in turn further increases myocardial ischemia.

Patients with cardiogenic shock in the setting of STEMI more often have multivessel disease, and myocardial ischemia may be present in multiple territories. It is for this reason that multivessel angioplasty may be of benefit in the patient with cardiogenic shock. Non-culprit or remote territories may also exhibit myocardial stunning in response to an ischemic insult which further reduces myocardial function. The pathophysiology of myocardial stunning is multifactorial and involves calcium overload in the sarcolemma and "stone heart" or diastolic dysfunction as well as the release of myocardial depressant substances. Areas of stunned myocardium may remain stunned after revascularization, but these regions do respond to inotropic stimulation. In contrast to stunned myocardium, hibernating myocardium does respond earlier to revascularization.

The multifactorial nature of cardiogenic shock can also be operative in the patient with critical aortic stenosis who has "spiraled": There is impairment of left ventricular outflow, with a drop in cardiac output there is greater subendocardial ischemia and poorer flow in the coronary arteries, this leads to further left ventricular systolic dysfunction, given the subendocardial ischemia, the left ventricle develops diastolic dysfunction and becomes harder to fill. Inadvertent administration of vasodilators and venodilators may further reduce cardiac output and accelerate or trigger such a spiral.

Pathophysiologic Mechanisms to Compensate for Cardiogenic shock

Cardiac output is the product of stroke volume and heart rate. In order to compensate for a reduction in stroke volume, there is a rise in the heart rate in patients with cardiogenic shock. As a result of the reduction in cardiac output, peripheral tissues extract more oxygen from the limited blood that does flow to them, and this leaves the blood deoxygenated when it returns to the right heart resulting in a fall in the mixed venous oxygen saturation.

Pathophysiology of Multiorgan Failure

The poor perfusion of organs results in hypoxia and metabolic acidosis. Inadequate perfusion to meet the metabolic demands of the brain, kidneys and heart leads to multiorgan failure.


++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++


Differential Diagnosis


Classification of shock based on hemodynamic parameters. (CO, cardiac output; CVP; central venous pressure; PAD, pulmonary artery diastolic pressure; PAS, pulmonary artery systolic pressure; RVD, right ventricular diastolic pressure; RVS, right ventricular systolic pressure; SVO2, systemic venous oxygen saturation; SVR, systemic vascular resistance.)[7][8]
Type of Shock Etiology CO SVR PCWP CVP SVO2 RVS RVD PAS PAD
Cardiogenic Acute Ventricular Septal Defect ↓↓ N — ↑ ↑↑ ↑ — ↑↑ N — ↑ N — ↑ N — ↑
Acute Mitral Regurgitation ↓↓ ↑↑ ↑ — ↑↑ N — ↑
Myocardial Dysfunction ↓↓ ↑↑ ↑↑ N — ↑ N — ↑ N — ↑
Right Ventricular Infarction ↓↓ N — ↓ ↑↑ ↓ — ↑ ↓ — ↑ ↓ — ↑
Obstructive Pulmonary Embolism ↓↓ N — ↓ ↑↑ ↓ — ↑ ↓ — ↑ ↓ — ↑
Cardiac Tamponade ↓ — ↓↓ ↑↑ ↑↑ N — ↑ N — ↑ N — ↑
Distributive Septic Shock N — ↑↑ ↓ — ↓↓ N — ↓ N — ↓ ↑ — ↑↑ N — ↓ N — ↓
Anaphylactic Shock N — ↑↑ ↓ — ↓↓ N — ↓ N — ↓ ↑ — ↑↑ N — ↓ N — ↓
Hypovolemic Volume Depletion ↓↓ ↓↓ ↓↓ N — ↓ N — ↓

References

  1. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977). "The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs". Circulation. 56 (5): 786–94. PMID 912839.
  2. Alonso DR, Scheidt S, Post M, Killip T (1973). "Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations". Circulation. 48 (3): 588–96. PMID 4726242.
  3. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA; et al. (2000). "Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?". J Am Coll Cardiol. 36 (3 Suppl A): 1063–70. PMID 10985706.
  4. Holmes DR, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC; et al. (1995). "Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries". J Am Coll Cardiol. 26 (3): 668–74. PMID 7642857.
  5. Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S (1993). "Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group". Am J Med. 94 (3): 265–73. PMID 8452150.
  6. Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C; et al. (1989). "The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group". J Am Coll Cardiol. 14 (1): 40–6, discussion 47-8. PMID 2738272.
  7. Parrillo, Joseph E.; Ayres, Stephen M. (1984). Major issues in critical care medicine. Baltimore: William Wilkins. ISBN 0-683-06754-0.
  8. Judith S. Hochman, E. Magnus Ohman (2009). Cardiogenic Shock. Wiley-Blackwell. ISBN 9781405179263.